Clinical trials of amyloid-based therapies for Alzheimer's disease.
Tariot
Pierre N
PN
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000187:drug effects / Q000502:physiology / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D018020:Lithium Compounds / Q000627:therapeutic use; D051379:Mice; D010446:Peptide Fragments / Q000187:drug effects / Q000502:physiology; D058225:Plaque, Amyloid / Q000187:drug effects* / Q000502:physiology; D014635:Valproic Acid / Q000627:therapeutic use
C437846:AN-1792; D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018020:Lithium Compounds; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D014635:Valproic Acid